Severe COVID-19 Pneumonia treated with Tocilizumab in a Pakistani population: Variables impacting Outcomes

Background: The association of severity of COVID-19 with raised Interleukin-6 (IL-6) levels led to Tocilizumab (TCZ) approval for treatment based on its IL-6 inhibiting mechanism of action. Treatment outcomes reported have been variable, with little data from Pakistan. Objective: To identify demog...

書誌詳細
出版年:	Journal of Liaquat National Hospital
主要な著者:	Sumaira Farman, Madeeha Habib Kamil Raja, Muhammad Kamil Hussain Raja, Syed Muhammad Daniyal Amjad, Muhammad Ahmed Saeed, Nadia Majeed, Nighat Mir Ahmad
フォーマット:	論文
言語:	英語
出版事項:	Liaquat National Hospital and Medical College 2024-04-01
主題:	coronavirus-19 covid-19 covid-19 pneumonia tocilizumab microthrombi il-6 anticoagulation
オンライン･アクセス:	https://journals.lnh.edu.pk/jlnh/pdf/b8804579-7acc-476e-9b2c-8eff9f4e5c8f.pdf

類似資料

Effect of Tocilizumab Treatment on Seroconversion in Hyperinflammation Secondary to Covid 19
著者:: Nilgün Işıksaçan, 等
出版事項: (2024-04-01)

Efficacy of Tocilizumab in Patients with COVID-19
著者:: Ahmad Alikhani, 等
出版事項: (2022-12-01)

Effectiveness of Tocilizumab in reducing inflammatory response associated with COVID-19 pneumonia at Islamabad Medical Complex, Islamabad
著者:: Abdul Naeem, 等
出版事項: (2023-04-01)

Tocilizumab in Combination with Corticosteroids in COVID-19 Pneumonia: A Single-Centre Retrospective Controlled Study
著者:: Zsófia Kardos, 等
出版事項: (2023-01-01)

Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort Study
著者:: Sibel BOLUKÇU, 等
出版事項: (2021-01-01)

Comparison of Tocilizumab and Anakinra in the Treatment of COVID-19: A Single-Center Experience
著者:: Bengisu Pınar Acat, 等
出版事項: (2022-08-01)

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
著者:: Francesco Perrone, 等
出版事項: (2020-10-01)

Prognostic significance of serum interleukin-6 in severe/critical COVID-19 patients treated with tocilizumab: a detailed observational study analysis
著者:: Panpan Liang, 等
出版事項: (2024-11-01)

Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia
著者:: Sameer Bansal, 等
出版事項: (2021-01-01)

The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review
著者:: Avi Gurion Kaye, 等
出版事項: (2020-11-01)

A Comprehensive Clinicopathological Analysis of the First Wave of COVID-19 in Slovakia
著者:: Lucia Krivosikova, 等
出版事項: (2025-02-01)

Tocilizumab for Severe COVID-19 Infection and Multisystem Inflammatory Syndrome in Adults and Children
著者:: Amber N. Edinoff, 等
出版事項: (2023-03-01)

Use of Immune Modulating Agents to Regulate Hyperinflammation in Severe COVID 19: Assessment of Tocilizumab Use in Combination with Steroids
著者:: Somayeh Sadeghi, 等
出版事項: (2024-10-01)

The effect of tocilizumab administration on inflammatory markers in COVID-19 patients
著者:: Engy Mohamed Riyad Soliman, 等
出版事項: (2024-08-01)

Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia
著者:: Daria Fomina, 等
出版事項: (2020-10-01)

Secondary Infection and Co-infection in COVID-19 Patients Receiving Tocilizumab
著者:: Çağla Erdoğan, 等
出版事項: (2024-06-01)

Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study
著者:: Cristina Mussini, 等
出版事項: (2023-01-01)

Tocilizumab Use among Patients Who Developed Pulmonary Embolism in the Course of Cytokine Release Storm and COVID-19 Pneumonia—A Retrospective Study
著者:: Daniel Chober, 等
出版事項: (2022-07-01)

Preliminary Efficacy of Tocilizumab Treatment in the Patients with COVID-19
著者:: Yu Chen, 等
出版事項: (2021-04-01)

Predictors of Mortality in Tocilizumab-Treated Severe COVID-19
著者:: Konstantinos Pagkratis, 等
出版事項: (2022-06-01)

Using Tocilizumab in Hematologic Malignant Patients with Severe COVID-19 Infection – Case Series Report
著者:: Fu C, 等
出版事項: (2024-01-01)

Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study
著者:: Abhyuday Kumar, 等
出版事項: (2024-05-01)

Clinical consequences of tocilizumab consumption time on COVID-19 patients
著者:: Shahin Keshtkar Rajabi, 等
出版事項: (2024-11-01)

Efficacy of tocilizumab treatment in severely ill COVID-19 patients
著者:: Jie Zhao, 等
出版事項: (2020-08-01)

Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19)
著者:: Sami Ullah, 等
出版事項: (2022-08-01)

A reduced fixed dose of Tocilizumab 200 mg compared to 400 mg in patients with severe COVID-19 disease
著者:: Stela COJOCARU, 等
出版事項: (2024-10-01)

Evaluating the efficacy of different doses of tocilizumab in treating critically ill COVID–19 patients: a single–center retrospective cohort study
著者:: Jie Gao, 等
出版事項: (2025-07-01)

Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial
著者:: José Aguareles, 等
出版事項: (2025-05-01)

Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19
著者:: Nastaran Injinari, 等
出版事項: (2024-10-01)

High Mortality Rate in Severe COVID-19 Despite Tocilizumab Administration: A Case Series
著者:: Cokorda Agung Wahyu Purnamasidhi, 等
出版事項: (2024-12-01)

Comparing the Effect of Tocilizumab and Methylprednisolone Pulse on Mortality and Outcomes in Patients with Severe COVID-19 in Bushehr
著者:: Razeah Rastegar, 等
出版事項: (2024-05-01)

Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study
著者:: Yuichi Kojima, 等
出版事項: (2022-04-01)

Tocilizumab in HIV patient with severe COVID-19: case report
著者:: Pedro Vieira Bertozzi, 等
出版事項: (2021-10-01)

Comparative effectiveness of tocilizumab vs standard care in patients with severe COVID-19-related pneumonia: a retrospective cohort study utilizing registry data as a synthetic control
著者:: Yukari Uemura, 等
出版事項: (2023-12-01)

Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group
著者:: Olivier Hermine, 等
出版事項: (2022-04-01)

Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports
著者:: Shazia Abdullah, 等
出版事項: (2021-08-01)

Incidence of secondary bacterial infections following utilization of tocilizumab for the treatment of COVID-19 – A matched retrospective cohort study
著者:: Joanna L Moore, 等
出版事項: (2021-01-01)

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
著者:: Annette Langer-Gould, 等
出版事項: (2020-10-01)

Response of Tocilizumab in Treating Severe to Critical COVID-19; Single-Centre Experience at a Tertiary Care Centre
著者:: Sarfaraz Khan, 等
出版事項: (2023-10-01)

Cedecea Davisae Bacteraemia after Tocilizumab Usage for Coronavirus Disease-2019 Treatment
著者:: İrem Akın Şen, 等
出版事項: (2021-09-01)